Cell-penetrating peptides and antibodies: a new direction for optimizing radioimmunotherapy
| العنوان: | Cell-penetrating peptides and antibodies: a new direction for optimizing radioimmunotherapy |
|---|---|
| المؤلفون: | Ganesh Venkatraman, Maneesh Jain, Surinder K. Batra |
| المصدر: | European Journal of Nuclear Medicine and Molecular Imaging. 34:973-977 |
| بيانات النشر: | Springer Science and Business Media LLC, 2007. |
| سنة النشر: | 2007 |
| مصطلحات موضوعية: | Metastatic breast, biology, business.industry, Colorectal cancer, medicine.drug_class, medicine.medical_treatment, Cell, General Medicine, medicine.disease, Monoclonal antibody, Targeted therapy, medicine.anatomical_structure, Antigen, Radioimmunotherapy, Immunology, Cancer research, medicine, biology.protein, Radiology, Nuclear Medicine and imaging, Antibody, business |
| الوصف: | Owing to their highly specific recognition of cognate antigens, antibodies have long been dream vehicles for targeted therapy and have recently been used to deliver radionuclides, drugs, toxins, and enzymes. Radioimmunotherapy (RIT) is an attractive therapeutic modality that combines the specificity of antibodies to antigens with the toxicity of the radionuclides. Radiolabeled antibodies like Bexxar and Zevalin have been approved by the FDA and are being used successfully to treat hematological malignancies in clinics. Moreover, because of their ability to inhibit the functional activity of the target antigen, some antibodies are also being used as unarmed therapeutics for solid tumors. Examples of these antibodies in clinics are: Avastin, an anti-VEGF monoclonal antibody that is used in the therapy of colorectal cancer, and Herceptin, an antiHer2 antibody approved for the therapy of Her2-overexpressing metastatic breast and other cancers. For solid tumors, however, radiolabeled antibody-based therapeutics have had limited success, primarily owing to slow uptake, poor penetration, and inadequate retention. Recent research efforts have centered on the strategies to overcome these limitations and optimize tumor uptake of armed antibodies. |
| تدمد: | 1619-7089 1619-7070 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::aa741e322f05f1f7a6f6bb9b42415f91Test https://doi.org/10.1007/s00259-007-0395-4Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi...........aa741e322f05f1f7a6f6bb9b42415f91 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16197089 16197070 |
|---|